{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:09:45Z","timestamp":1791828585265,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T00:00:00Z","timestamp":1546905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Spanish Ministry of Health"},{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-018-1772-z","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T10:48:16Z","timestamp":1546944496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis"],"prefix":"10.1186","volume":"21","author":[{"name":"The REDES-TNF investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Gratac\u00f3s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3274-6048","authenticated-orcid":false,"given":"Caridad","family":"Pontes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Juanola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Avenda\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Vallano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"de Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimon","family":"Sanmart\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,8]]},"reference":[{"issue":"1","key":"1772_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G","volume":"41","author":"J Braun","year":"1998","unstructured":"Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998;41(1):58\u201367.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1772_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0049-0172(05)80011-3","volume":"22","author":"JT Gran","year":"1993","unstructured":"Gran JT, Husby G. The epidemiology of ankylosing spondylitis. Semin Arthritis Rheum. 1993;22(5):319\u201334.","journal-title":"Semin Arthritis Rheum"},{"issue":"6 Suppl 28","key":"1772_CR3","first-page":"S16","volume":"20","author":"J Braun","year":"2002","unstructured":"Braun J, Pincus T. Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol. 2002;20(6 Suppl 28):S16\u201322.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"1772_CR4","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/acr.22730","volume":"68","author":"JD Castillo-Ortiz","year":"2016","unstructured":"Castillo-Ortiz JD, Ramiro S, Landewe R, van der Heijde D, Dougados M, van den Bosch F, Boonen A. Work outcome in patients with ankylosing spondylitis: results from a 12-year followup of an international study. Arthritis Care Res (Hoboken). 2016;68(4):544\u201352.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"1772_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P, Kavanaugh A, Kvien TK, Landewe R, Luger T, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73(1):6\u201316.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1772_CR6","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s10067-005-0132-y","volume":"25","author":"J Zochling","year":"2006","unstructured":"Zochling J, Bohl-Buhler MH, Baraliakos X, Feldtkeller E, Braun J. Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis\u2013a population-based survey. Clin Rheumatol. 2006;25(6):794\u2013800.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"1772_CR7","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/rheumatology\/ken094","volume":"47","author":"LC Coates","year":"2008","unstructured":"Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, Emery P, Marzo-Ortega H. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology (Oxford). 2008;47(6):897\u2013900.","journal-title":"Rheumatology (Oxford)"},{"issue":"19","key":"1772_CR8","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275\u201385.","journal-title":"JAMA"},{"issue":"2","key":"1772_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.reuma.2010.02.001","volume":"7","author":"N Busquets","year":"2011","unstructured":"Busquets N, Carmona L, Suris X. Systematic review: safety and efficacy of anti-TNF in elderly patients. Reumatol Clin. 2011;7(2):104\u201312.","journal-title":"Reumatol Clin"},{"issue":"4","key":"1772_CR10","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1136\/annrheumdis-2015-208490","volume":"75","author":"L Dreyer","year":"2016","unstructured":"Dreyer L, Magyari M, Laursen B, Cordtz R, Sellebjerg F, Locht H. Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry. Ann Rheum Dis. 2016;75(4):785\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1772_CR11","doi-asserted-by":"publisher","first-page":"R439","DOI":"10.1186\/ar1693","volume":"7","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther. 2005;7(3):R439\u201344.","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 10","key":"1772_CR12","first-page":"S1785","volume":"60","author":"V Torrente","year":"2009","unstructured":"Torrente V, Gratacos J, Juanola X, Sanmarti R, Suarez D, Moreno M. Infliximab withdrawal in patients with spondyloarthritis who presented criteria of clinical disease remission. an open study of clinical practise (REMINEA). Arthritis Rheum. 2009;60(Suppl 10):S1785.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1772_CR13","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/rheumatology\/keh475","volume":"44","author":"J Brandt","year":"2005","unstructured":"Brandt J, Listing J, Haibel H, Sorensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford). 2005;44(3):342\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"1772_CR14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s10067-011-1722-5","volume":"30","author":"V Navarro-Compan","year":"2011","unstructured":"Navarro-Compan V, Moreira V, Ariza-Ariza R, Hernandez-Cruz B, Vargas-Lebron C, Navarro-Sarabia F. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol. 2011;30(7):993\u20136.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"1772_CR15","first-page":"558","volume":"33","author":"S Keeling","year":"2006","unstructured":"Keeling S, Oswald A, Russell AS, Maksymowych WP. Prospective observational analysis of the efficacy and safety of low-dose (3 mg\/kg) infliximab in ankylosing spondylitis: 4-year followup. J Rheumatol. 2006;33(3):558\u201361.","journal-title":"J Rheumatol"},{"issue":"7","key":"1772_CR16","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1093\/rheumatology\/keu461","volume":"54","author":"I Gonzalez-Alvaro","year":"2015","unstructured":"Gonzalez-Alvaro I, Martinez-Fernandez C, Dorantes-Calderon B, Garcia-Vicuna R, Hernandez-Cruz B, Herrero-Ambrosio A, Ibarra-Barrueta O, Martin-Mola E, Monte-Boquet E, Morell-Baladron A, et al. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Rheumatology (Oxford). 2015;54(7):1200\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1772_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/rheumatology\/kev298","volume":"55","author":"DY Chen","year":"2016","unstructured":"Chen DY, Chen YM, Hsieh TY, Hung WT, Hsieh CW, Chen HH, Tang KT, Lan JL. Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up. Rheumatology (Oxford). 2016;55(1):143\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1772_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/BOR.0000000000000180","volume":"27","author":"WP Maksymowych","year":"2015","unstructured":"Maksymowych WP. Biomarkers in axial spondyloarthritis. Curr Opin Rheumatol. 2015;27(4):343\u20138.","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"1772_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1772_CR20","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1136\/annrheumdis-2015-208593","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Portier A, Landewe R, Etcheto A, Navarro-Compan V, Kroon F, van der Heijde D, Dougados M. Preliminary definitions of \u2018flare\u2019 in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative. Ann Rheum Dis. 2016;75(6):991\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1772_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.reuma.2010.12.002","volume":"7","author":"X Juanola Roura","year":"2011","unstructured":"Juanola Roura X, Zarco Montejo P, Sanz Sanz J, Munoz Fernandez S, Mulero Mendoza J, Linares Ferrando LF, Gratacos Masmitja J, Garcia de Vicuna R, Fernandez Carballido C, Collantes Estevez E, et al. Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in spondyloarthritis except for psoriatic arthritis. Reumatol Clin. 2011;7(2):113\u201323.","journal-title":"Reumatol Clin"},{"key":"1772_CR22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s13063-015-0828-5","volume":"16","author":"C Pontes","year":"2015","unstructured":"Pontes C, Gratacos J, Torres F, Avendano C, Sanz J, Vallano A, Juanola X, de Miguel E, Sanmarti R, Calvo G. Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): study protocol for a randomized controlled trial. Trials. 2015;16:370.","journal-title":"Trials"},{"issue":"10","key":"1772_CR23","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1136\/ard.2007.073569","volume":"66","author":"F Conti","year":"2007","unstructured":"Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, Scrivo R, Valesini G. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis. 2007;66(10):1393\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1772_CR24","unstructured":"Elashoff JD. nQuery\u00a0Version 7.0 Advisor User\u2019s Guide. Statistical Solutions Ltd, Los Angeles, CA;\u00a02007."},{"issue":"8","key":"1772_CR25","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","volume":"17","author":"RG Newcombe","year":"1998","unstructured":"Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17(8):873\u201390.","journal-title":"Stat Med"},{"issue":"10","key":"1772_CR26","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s10067-010-1542-z","volume":"29","author":"J Lee","year":"2010","unstructured":"Lee J, Noh JW, Hwang JW, Oh JM, Kim H, Ahn JK, Lee YS, Cha HS, Koh EM. Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. Clin Rheumatol. 2010;29(10):1149\u201354.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"1772_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/annrheumdis-2014-205202","volume":"75","author":"J Zavada","year":"2016","unstructured":"Zavada J, Uher M, Sisol K, Forejtova S, Jarosova K, Mann H, Vencovsky J, Pavelka K. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. Ann Rheum Dis. 2016;75(1):96\u2013102.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1772_CR28","first-page":"80","volume":"32","author":"S Pavy","year":"2005","unstructured":"Pavy S, Brophy S, Calin A. Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study. J Rheumatol. 2005;32(1):80\u20135.","journal-title":"J Rheumatol"},{"issue":"4","key":"1772_CR29","first-page":"732","volume":"33","author":"G Kobelt","year":"2006","unstructured":"Kobelt G, Andlin-Sobocki P, Maksymowych WP. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada. J Rheumatol. 2006;33(4):732\u201340.","journal-title":"J Rheumatol"},{"issue":"8","key":"1772_CR30","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","volume":"73","author":"S Ramiro","year":"2014","unstructured":"Ramiro S, van der Heijde D, van Tubergen A, Stolwijk C, Dougados M, van den Bosch F, Landewe R. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014;73(8):1455\u201361.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1772_CR31","doi-asserted-by":"publisher","first-page":"e0168958","DOI":"10.1371\/journal.pone.0168958","volume":"11","author":"JW Park","year":"2016","unstructured":"Park JW, Kwon HM, Park JK, Choi JY, Lee EB, Song YW, Lee EY. Impact of dose tapering of tumor necrosis factor inhibitor on radiographic progression in ankylosing spondylitis. PLoS One. 2016;11(12):e0168958.","journal-title":"PLoS One"},{"issue":"6","key":"1772_CR32","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1080\/17425255.2017.1320390","volume":"13","author":"C Bouman","year":"2017","unstructured":"Bouman C, van Herwaarden N, van den Hoogen F, van der Maas A, van den Bemt B, den Broeder AA. Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement. Expert Opin Drug Metab Toxicol. 2017;13(6):597\u2013604.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"1772_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3109\/03009742.2015.1114666","volume":"45","author":"AF Marsman","year":"2016","unstructured":"Marsman AF, Kneepkens EL, Ruwaard J, Wei JC, Nurmohamed MT, van Denderen C, van der Horst-Bruinsma IE, Rispens T, Wolbink G. Search for a concentration-effect curve of adalimumab in ankylosing spondylitis patients. Scand J Rheumatol. 2016;45(4):331\u20134.","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"1772_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/BOR.0b013e328352b7bd","volume":"24","author":"D Poddubnyy","year":"2012","unstructured":"Poddubnyy D, Sieper J. Radiographic progression in ankylosing spondylitis\/axial spondyloarthritis: how fast and how clinically meaningful? Curr Opin Rheumatol. 2012;24(4):363\u20139.","journal-title":"Curr Opin Rheumatol"},{"key":"1772_CR35","unstructured":"International Conference on Harmonisation. ICH: E 6 (R1): Guideline for good clinical practice - Step 5. [\n                    https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf\n                    \n                  ]. Last access:\u00a030th November\u00a02018."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1772-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1772-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1772-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T19:24:53Z","timestamp":1578425093000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1772-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,8]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1772"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1772-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,8]]},"assertion":[{"value":"1 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial was performed according to the study protocol and protocol amendments, which were approved by the Ethics Committee for Clinical Research of the participating sites and by the Spanish Agency for Medicines and Health Products, and complied with the ethical principles of biomedical research, Good Clinical Practice [] and applicable Spanish legislation. Two amendments to the protocol reflected in the clinical trial registration sites were implemented after recruitment was initiated, which referred to inclusion of new investigators and recruiting sites, and to allow collection of blood samples for measurement of inflammatory mediators, drug plasma measurements and ADA.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final version and consent to publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No author has received any private funding, nor has any been influenced in the preparation of the manuscript. The following authors declare that they have no competing interests: CP, FT, CAS, AV and GC. In the past 2\u2009years, JG has received grants to attend congresses and educational courses, has obtained fees for scientific consultancies and has received speaking fees and fees for participation in educational programmes from the following companies: Roche, MSD, Pfizer, AbbVie, Janssen Cilag, UCB Pharma, Novartis and Celgene. EdM has received grant\/research support from AbbVie and Pfizer, honorarium as a speaker from Abbvie, MSD and Novartis and consultant fees from Abbvie and Novartis. JS has obtained grants to attend congresses, speaking fees and fees for participation in educational programmes from Abbvie, Pfizer, MSD, Roche, UCB and Menarini. XJ has attended advisory board meetings of Celgene, has received investigational grants from Abbvie and Pfizer and has received fees for participation in educational programmes from MSD, Pfizer and Abbvie. RS has received speaking fees and fees for attending advisory boards from Abbott\/Abbvie, Bristol-Myers Squibb, MSD, Roche, UCB and Pfizer, investigational grants from Bristol-Myers Squibb, MSD, Roche, UCB, Pfizer, FER and SCR and funding for educational projects from MSD, Bristol-Myers Squibb and Abbvie.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"11"}}